These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 23891627

  • 1. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD.
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [Abstract] [Full Text] [Related]

  • 2. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD.
    Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
    [Abstract] [Full Text] [Related]

  • 3. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [Abstract] [Full Text] [Related]

  • 4. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [Abstract] [Full Text] [Related]

  • 5. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
    Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.
    Br J Cancer; 2015 Sep 29; 113(7):1020-6. PubMed ID: 26325104
    [Abstract] [Full Text] [Related]

  • 6. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD.
    Mol Cancer Ther; 2015 Nov 29; 14(11):2519-26. PubMed ID: 26333383
    [Abstract] [Full Text] [Related]

  • 7. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
    Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
    Tumour Biol; 2015 Jul 29; 36(7):5505-13. PubMed ID: 25669172
    [Abstract] [Full Text] [Related]

  • 8. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB.
    Gynecol Oncol; 2016 Jun 29; 141(3):570-579. PubMed ID: 27017985
    [Abstract] [Full Text] [Related]

  • 9. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.
    Mol Cancer Ther; 2011 Dec 29; 10(12):2426-36. PubMed ID: 21998291
    [Abstract] [Full Text] [Related]

  • 10. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Neuro Oncol; 2019 Nov 04; 21(11):1401-1411. PubMed ID: 31173106
    [Abstract] [Full Text] [Related]

  • 11. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.
    Clin Cancer Res; 2012 Dec 15; 18(24):6771-83. PubMed ID: 23136191
    [Abstract] [Full Text] [Related]

  • 12. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD.
    Gynecol Oncol; 2014 Oct 15; 135(1):142-8. PubMed ID: 25124161
    [Abstract] [Full Text] [Related]

  • 13. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD.
    Gynecol Oncol; 2021 Nov 15; 163(2):334-341. PubMed ID: 34452746
    [Abstract] [Full Text] [Related]

  • 14. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
    Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD.
    Br J Cancer; 2016 Jul 26; 115(3):303-11. PubMed ID: 27351214
    [Abstract] [Full Text] [Related]

  • 15. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
    Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
    Br J Cancer; 2014 Oct 28; 111(9):1750-6. PubMed ID: 25268372
    [Abstract] [Full Text] [Related]

  • 16. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Br J Cancer; 2011 Oct 11; 105(8):1176-82. PubMed ID: 21915118
    [Abstract] [Full Text] [Related]

  • 17. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
    Menderes G, Clark M, Santin AD.
    Discov Med; 2016 Apr 11; 21(116):293-303. PubMed ID: 27232515
    [Abstract] [Full Text] [Related]

  • 18. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
    Mahdi H, Xiu J, Reddy SK, DeBernardo R.
    J Surg Oncol; 2015 Aug 11; 112(2):188-94. PubMed ID: 26250968
    [Abstract] [Full Text] [Related]

  • 19. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
    Hayes MP, Douglas W, Ellenson LH.
    Gynecol Oncol; 2009 Jun 11; 113(3):370-3. PubMed ID: 19272638
    [Abstract] [Full Text] [Related]

  • 20. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J, Wang H, Yao J, Zou X.
    Pharmazie; 2014 Jan 11; 69(1):38-42. PubMed ID: 24601221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.